Navigation Links
Common diabetes drug may halt growth of cysts in polycystic kidney disease
Date:11/11/2010

INDIANAPOLIS Researchers report that a drug commonly used to treat diabetes may also retard the growth of fluid-filled cysts of the most common genetic disorder, polycystic kidney disease. PKD does not discriminate by gender or race and affects one in 1,000 adults worldwide.

Researchers from the schools of Science and Medicine at Indiana University-Purdue University Indianapolis and colleagues from the Mayo Clinic report this month in the online peer-reviewed journal PPAR Research that pioglitazone appears to control the growth of PKD cysts.

Using a rat model that has the same genetic mutation as a form of human PKD, the two research groups independently tested a pioglitazone treatment regimen and found that it slowed down both kidney and liver cyst growth by inhibiting a chloride channel in the cells of these organs.

Normally pioglitazone works by making the body more sensitive to its own insulin. However, in studying why this class of drugs causes fluid retention, Bonnie L. Blazer-Yost, Ph.D., professor of biology at the IUPUI School of Science and corresponding author of the new study, serendipitously found that it also inhibits a chloride channel.

"We thought that since this class of drugs inhibits the body's chloride channels, then it would be a good candidate to treat PKD, a disease in which excessive chloride and water are transported into the cysts of the kidneys and the liver causing them to expand," said Blazer-Yost, Ph.D.

A normal kidney is the size of a fist. A polycystic kidney is the size of a football. Currently there is no cure for PKD and therapy options are limited. Organ transplantation is the most common treatment.

"The idea of using a chloride channel inhibitor to treat PKD is not new. What is new is our finding that an insulin sensitizing agent like piogltiazone inhibits chloride channels. The finding that pioglitazone, which has already been approved by the Food and Drug Administration for diabetes, can halt cyst progression and may be an effective and well-tolerated treatment for this chronic disease, is exciting. Confirmation of these results in other animal models of PKD would be a useful next step.

"We know from long-term experience that this drug has a good safety profile. Strategies that minimize adverse events are important when considering treatments for a chronic disease such as PKD," said Blazer-Yost, a physiologist who hopes that human trials of pioglitazone therapy for PKD can be conducted in the near future.


'/>"/>

Contact: Cindy Fox Aisen
caisen@iupui.edu
317-274-7722
Indiana University School of Medicine
Source:Eurekalert  

Related biology news :

1. New book examines health and environmental impacts of common (and not-so-common) chemicals
2. Scientists describe new approach for identifying genetic markers for common diseases
3. Researchers find first genetic evidence for loss of teeth in the common ancestor of baleen whales
4. First genetic link to common migraine exposed
5. Low bone mineral density common in children and teenagers with inflammatory bowel disease
6. Scientists find new twist on drug screening to treat common childhood cancer
7. Common orchid gives scientists hope in face of climate change
8. Pancreatic cancers use fructose, common in the Western diet, to fuel their growth
9. Rare and common genetic variations responsible for high triglyceride levels in blood
10. Heat waves could be commonplace in the US by 2039, Stanford study finds
11. New rust resistance genes added to common beans
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Common diabetes drug may halt growth of cysts in polycystic kidney disease
(Date:12/2/2016)... Dec. 1, 2016   SoftServe , a ... BioLock , an electrocardiogram (ECG) biosensor analysis system ... key IoT asset. The smart system ensures device-to-device ... steering wheel and mobile devices to easily ,recognize, ... As vehicle technology advances, so too must ...
(Date:11/29/2016)... , Nov. 29, 2016 BioDirection, a ... point-of-care products for the objective detection of concussion and ... company has successfully completed a meeting with the U.S. ... Tbit™ blood test Pre-Submission Package. During the meeting company ... system as a precursor to commencement of a planned ...
(Date:11/28/2016)... "The biometric system market ... The biometric system market is in the growth stage ... future. The biometric system market is expected to be ... CAGR of 16.79% between 2016 and 2022. Government initiative ... in smartphones, rising use of biometric technology in financial ...
Breaking Biology News(10 mins):
(Date:11/30/2016)... York , November 30, 2016 ... as a few players hold a dominant share in ... Charles River Laboratories International, Inc., and Merck KGaA, held ... in 2015. Transparency Market Research observes that these companies ... focused on development products that are do not require ...
(Date:11/30/2016)... Fla. , Nov. 30, 2016 Biotest ... products, is pleased to announce the addition of its ... Kearney, Nebraska . The 15,200 square ... on November 29th, 2016 and brings the total number ... Ileana Carlisle , BPC,s Chief Executive Officer ...
(Date:11/30/2016)... /PRNewswire/ -  Equicare Health Inc ., the leading supplier ... one of the top 100 companies in the 2016 ... distinguishes the top digital health companies across the globe. ... this year continually upgrading our product with the ongoing ... team," says Len Grenier , CEO of Equicare ...
(Date:11/30/2016)... BEIJING , Nov. 30, 2016 /PRNewswire/ ... of genomic services and solutions with cutting edge next-generation ... has completed a USD $75 Million [515 Million RMB] ... CMB International Capital Management ( Shenzhen ) ... Ltd. ("SDIC Innovation") and Shanghai Sigma Square Investment Center ...
Breaking Biology Technology: